These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 38325629

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK, Bhatt DL, Montvida O.
    Eur Heart J; 2021 May 07; 42(18):1728-1738. PubMed ID: 33289789
    [Abstract] [Full Text] [Related]

  • 24. Incretin-based therapy and the risk of diabetic foot ulcers and related events.
    Werkman NCC, Driessen JHM, Klungel OH, Schaper NS, Souverein PC, Stehouwer CDA, Nielen JTH.
    Diabetes Obes Metab; 2024 Sep 07; 26(9):3764-3780. PubMed ID: 38951877
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
    Yang JY, Wang T, Pate V, Gower EW, Crowley MJ, Buse JB, Stürmer T.
    Diabetes Obes Metab; 2019 May 07; 21(5):1223-1236. PubMed ID: 30697897
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
    Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, Marsolo K, Shah RC, Jones WS, Gordon H, Hwang W, Ayoub I, Ford D, Chamberlain A, Rao A, Fonseca V, Chang A, Ahmad F, Hung A, Hunt K, Butler J, Bosworth HB, Pagidipati N.
    J Am Coll Cardiol; 2024 Aug 20; 84(8):696-708. PubMed ID: 39142723
    [Abstract] [Full Text] [Related]

  • 31. Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors.
    Lin DS, Yu AL, Lo HY, Lien CW, Lee JK, Chen WJ.
    Diabetologia; 2022 Dec 20; 65(12):2032-2043. PubMed ID: 35945333
    [Abstract] [Full Text] [Related]

  • 32. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J, Lee S, Leung KSK, Wai AKC, Liu T, Liu Y, Chang D, Wong WT, Wong ICK, Cheung BMY, Zhang Q, Tse G.
    ESC Heart Fail; 2022 Apr 20; 9(2):1388-1399. PubMed ID: 35132823
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J.
    Cardiovasc Diabetol; 2022 Nov 05; 21(1):232. PubMed ID: 36335326
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y, Tsoi MF, Cheung BMY.
    Cardiovasc Diabetol; 2019 Aug 28; 18(1):112. PubMed ID: 31462224
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, Ghuman R, Cuthbertson DJ, Lip GYH, Alam U.
    Diabetes Obes Metab; 2023 Oct 28; 25(10):2897-2909. PubMed ID: 37385958
    [Abstract] [Full Text] [Related]

  • 40. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
    Li J, Albajrami O, Zhuo M, Hawley CE, Paik JM.
    Clin J Am Soc Nephrol; 2020 Nov 06; 15(11):1678-1688. PubMed ID: 32518100
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.